The study uses several cancer medicines, depending on the specific change found in the tumor. These include olaparib, erlotinib, crizotinib, trametinib, pemigatinib, selpercatinib, axitinib, vismodegib, pembrolizumab, larotrectinib, dabrafenib, and the injection Phesgo (trastuzumab and pertuzumab). Standard care medicines in the study include oxaliplatin, capecitabine, irinotecan, fluorouracil, calcium folinate, gemcitabine, and paclitaxel albumin-bound. Some medicines are taken by mouth, while others are given by injection or infusion into a vein.

During the study, people are assigned to receive either the tailored treatment or standard care. Treatment is given in repeated cycles, with regular medical visits to check health, side effects, and how the cancer is doing. The study follows people over time to see how long the cancer stays under control and how the treatments compare in safety and overall benefit.

The purpose of the study is to determine whether this cell‑based therapy can improve how long patients live without the disease getting worse and ultimately increase overall survival. After the chemotherapy course, the cell infusion is administered, followed by surgery to remove the tumor when possible. Patients are then monitored over time to see if the cancer returns, using imaging criteria called RECIST 1.1, and to assess quality of life and safety. The follow‑up period includes regular doctor visits, scans, and blood tests to track the immune response and any side effects.

The investigation uses a specialized technique known as PET, which is a type of scan used to visualize how certain substances work inside the body. During the process, the substance [68Ga]BED003 is administered through an intravenous injection, meaning it is delivered directly into a vein. This substance is designed to target a specific protein found in certain tumor environments to help create clearer images. The scans are often combined with a computed tomography, which uses X-rays to create detailed pictures of the body’s internal structures.

Participants in the study will undergo imaging to see how well the new substance can identify cancer cells within the peritoneum, which is the thin layer of tissue that lines the inner wall of the abdomen and covers most of the organs. The study will monitor how the imaging agent behaves over time and check for any side effects. The goal is to determine if this new method can provide more accurate information about the presence and location of these cancers compared to standard medical practices.

The purpose of the study is to compare these two sedation approaches to see which one works better and is safer during endoscopic ultrasound procedures. Patients participating in the study will be randomly assigned to receive either remimazolam or propofol for their sedation. The study will look at whether patients experience any problems with their heart or breathing during the procedure, such as low oxygen levels, changes in blood pressure, irregular heartbeat, or changes in heart rate. The medications will be given through a vein, and remimazolam can be given up to a total of 33 milligrams while propofol will be given at a rate based on the patient’s weight.

The study will also examine other aspects of the sedation experience, including how satisfied patients and doctors are with the quality of sedation, how long it takes to start the procedure, how quickly patients wake up afterward, how much time is spent in the recovery area, and whether any additional medications are needed. The study will track if patients experience pain when the medication is injected, whether they need to stay in the hospital, and whether any breathing support is required. Information will also be collected about the costs of the different sedation approaches, including the price of medications, staff time, and how long the procedure rooms are occupied.

Patients in this study will receive zanidatamab on its own, without combining it with other cancer treatments. The medicine will be given regularly over a treatment period that can last up to 60 weeks. The doctors will check how the tumors respond to the treatment by doing regular scans and tests. Some patients in the study may have breast cancer or cancers of the stomach and food pipe area, and they may have received a specific type of HER2-targeted therapy before, which is a treatment that works against the HER2 protein. For other types of solid tumors, patients should not have had this type of treatment before.

During the study, doctors will monitor patients carefully to see if the treatment is working and to watch for any side effects. This includes checking heart function, blood tests to see how the liver and kidneys are working, and measuring the size of the tumors. Patients will also be asked about symptoms they experience using questionnaires. The study will look at how many patients see their tumors shrink, how long the treatment keeps working, and how long patients live. Blood samples will be taken to measure the amount of medicine in the body and to check if the body makes any reaction against the medicine.

The process involves using the Extroducer to administer gemcitabine directly near the cancerous growth. During the study, researchers will monitor for any serious adverse events, which are unexpected and significant health problems, and track how the body responds to the treatment. The study also looks at changes in tumor markers, which are substances found in the blood that can indicate the presence or activity of cancer, and evaluates the overall quality of life during the course of the treatment.

During the study, participants will receive an intravenous injection, meaning the substance is delivered directly into a vein. After the injection, the imaging process will be performed to look for signs of cancer in the abdominal area. The effectiveness of the GEH300079 (68Ga) injection will be compared to standard imaging methods currently used in medical practice to see if this new method provides more accurate information about the presence and location of cancer cells.

The purpose of this study is to determine if a combined treatment called the HOP bundle can reduce major complications after pancreatoduodenectomy surgery. This bundle consists of three components: hydrocortisone (a steroid medication that reduces inflammation), octreotide (a medication that reduces pancreatic secretions), and a teres ligament patch (a piece of tissue used to reinforce the surgical connection).

Participants in the study will undergo pancreatoduodenectomy surgery and will be randomly assigned to either receive the HOP bundle treatment or standard care. The researchers will monitor patients for various complications that can occur after this type of surgery, including pancreatic fistula (leakage of pancreatic fluid), delayed gastric emptying (slow emptying of the stomach), post-pancreatectomy hemorrhage (bleeding after surgery), and other potential issues.

In this study, two medications are being used. The first is Plavix, which contains the active ingredient clopidogrel and is taken as a film-coated tablet. The second is Fragmin, which contains dalteparin sodium and is given as an injection. The purpose of the study is to see if adding antiplatelet therapy to the usual treatment can more effectively prevent blood clots in patients with pancreatic cancer.

Participants in the study will receive either the standard treatment alone or the standard treatment plus the antiplatelet therapy. The study will last for up to 12 months, during which time the safety and effectiveness of the treatments will be monitored. The goal is to determine if the combination of treatments can reduce the risk of blood clots without causing significant side effects, such as major bleeding.

Participants in the study will receive one of two types of chemotherapy. One group will receive a treatment guided by the analysis of their tumor after surgery, while the other group will receive a standard treatment called mFOLFIRINOX, regardless of the tumor analysis. The medications used in this study include Levoleucovorin (also known as Elvorine), Paclitaxel (known as Apexelsin), Gemcitabine, Irinotecan, Fluorouracil, and Oxaliplatin. These medications are administered through an intravenous infusion, which means they are given directly into a vein.

The study will take place over several months, with participants receiving treatment in cycles. The effects of the treatments will be monitored to determine their impact on the patients’ health and quality of life. Some participants may receive a placebo as part of the study. The trial will help researchers understand which treatment approach is more effective for patients with resected pancreatic adenocarcinoma following neoadjuvant chemotherapy.

The chemotherapy drugs that will be combined with sotorasib include paclitaxel, oxaliplatin, fluorouracil, calcium folinate, irinotecan, and gemcitabine. Sotorasib is taken as tablets by mouth, while the chemotherapy medications are given through an intravenous infusion (through a vein). The purpose of this study is to determine if this combination of treatments is safe and well-tolerated by patients.

During the study, patients will receive sotorasib tablets daily along with their scheduled chemotherapy treatments. Doctors will monitor patients’ health through regular check-ups, blood tests, and imaging scans to assess how well the treatment is working and to watch for any side effects. The treatment may continue for up to 9 months, depending on how well the patient responds and tolerates the medications.

The purpose of the study is to evaluate how well the 68Ga-FAPI-46 PET imaging works in detecting gastrointestinal cancers. Participants in the study will undergo this imaging process, which is designed to provide clear pictures of the cancerous regions. The study will compare the results of this new imaging method with previous standard imaging techniques to see if it offers better detection of cancer locations.

Throughout the study, the safety of the 68Ga-FAPI-46 PET imaging will be monitored, including any side effects that may occur. The study will also assess how the imaging results might influence treatment decisions made by doctors. This research aims to improve the understanding of how effective this imaging method is in identifying and managing gastrointestinal cancers.

The purpose of this study is to evaluate which treatment approach is more effective in terms of overall survival, which means the length of time patients live after starting the treatment. Patients will be randomly assigned to one of the two treatment groups. The study will involve regular visits to the clinic for treatment administration and monitoring. Treatments will be given through an infusion, which is a method of delivering medication directly into the bloodstream over a period of time. The study will also monitor the quality of life and any side effects experienced by the patients.

Participants in the study will be closely monitored by healthcare professionals throughout the treatment period. The study aims to provide valuable information on the best treatment strategy for patients with advanced pancreatic cancer, potentially leading to improved care and outcomes for future patients. The trial is expected to continue until 2028, with recruitment starting in 2024.

The purpose of the study is to learn more about how well the treatment works and how safe it is for participants. The study will involve taking the medication by mouth for a period of up to 36 months. Participants will be monitored regularly to see how their tumors respond to the treatment and to check for any side effects. The study will also look at how long the treatment keeps the disease under control and how it affects the overall health and quality of life of the participants.

Participants in the study will have regular check-ups and tests to track their progress. These tests will help researchers understand the effectiveness of the treatment and any potential risks. The study aims to provide valuable information that could lead to better treatment options for people with these types of tumors in the future.

The purpose of the study is to evaluate how well electrochemotherapy works when followed by standard chemotherapy, compared to using only standard chemotherapy. The study will use a minimally invasive surgical technique called laparoscopy, which involves small incisions and is less risky than traditional open surgery. This approach aims to make the treatment more accessible and safer for patients.

Participants in the study will receive either the combination of electrochemotherapy and standard chemotherapy or just the standard chemotherapy. The study will monitor the response of the cancer to the treatments, as well as the impact on the patient’s quality of life, including pain levels. The study will also assess the safety of electrochemotherapy and its potential to make the cancer operable. The trial is expected to continue until 2030, with recruitment starting in 2024.

Participants in the study will receive these treatments over a period of up to 12 months. The study will monitor how the cancer responds to the treatment, looking for signs of complete or partial response, or if the disease remains stable for at least 16 weeks. The study will also assess the safety of the treatments and any side effects that may occur. Participants will undergo regular assessments to track their progress and any changes in their condition.

The trial aims to gather information on the effectiveness of the treatment combination and its impact on the quality of life for those with pancreatic cancer that has spread to the peritoneum. The study will also explore various aspects of the treatment, such as how the drugs are absorbed in the body and their effects on the cancer cells. This research could provide valuable insights into new ways to manage and treat this type of cancer.

Participants in the study will have already completed at least four months of FOLFIRINOX treatment without their cancer progressing. The study will involve regular visits to monitor the participants’ health and the progression of their cancer. The main goal is to see how long participants can live without their cancer getting worse, which is referred to as Progression Free Survival (PFS). This will be measured from the time of the first treatment with Ampligen until the cancer progresses, the participant passes away, or the study ends.

The study is designed to last for several years, with an estimated completion date in 2028. Participants will be closely monitored throughout the study to ensure their safety and to gather data on the effectiveness of Ampligen in treating locally advanced pancreatic cancer. This research aims to provide valuable insights into potential new treatment options for this challenging condition.

The purpose of the study is to compare the overall survival of patients receiving the new treatment combination against those receiving the placebo combination. Participants in the study will receive their treatments through an intravenous route, which means the medication is given directly into a vein. The study will be conducted over a period of up to 24 months, during which patients will be monitored for their response to the treatment and any side effects they may experience.

Overall survival, which is the time from the start of the study until death from any cause, is the main focus of the study. Other aspects being looked at include how long patients live without the disease getting worse, the rate at which patients respond to the treatment, and the duration of any positive response. The study will also track the safety of the treatments by recording any adverse events or serious side effects. This trial aims to provide valuable information on the effectiveness and safety of Quemliclustat in combination with chemotherapy for treating metastatic pancreatic cancer.

Participants in the study will take Digitoxin tablets by mouth. The study will last for up to one year, during which time the participants’ health and response to the treatment will be closely monitored. The study will look at how long patients live without the cancer getting worse, as well as their overall survival. Researchers will also assess the safety of the treatment and any side effects that may occur.

Throughout the study, various health assessments will be conducted, including checking blood markers that can indicate the presence of cancer. The quality of life of participants will also be evaluated using specific questionnaires. Additionally, the study will involve analyzing certain proteins in the blood that are important for cancer and inflammation. This research aims to provide valuable insights into the potential benefits of using Digitoxin alongside chemotherapy for treating pancreatic cancer.

The purpose of the study is to understand how these medications might reduce the risk of blood clots and improve the overall outlook for patients with pancreatic cancer. Participants will receive one of the medications or a placebo during their neoadjuvant treatment. The study will monitor the occurrence of blood clots, any bleeding complications, and the progression of the disease. Patients will be followed for at least five years or until they pass away.

Throughout the study, blood samples will be collected at various times to observe changes in blood clotting activity. These samples will be taken before starting neoadjuvant treatments, between chemotherapy cycles, after these treatments, and at several intervals during the follow-up period. This research hopes to provide valuable insights into the prevention of blood clots in pancreatic cancer patients and its potential impact on their survival and quality of life.

The purpose of the study is to evaluate the effectiveness and safety of this combination of treatments in patients who have not received prior treatment for their metastatic pancreatic cancer. Participants in the study will receive these treatments over a period of time, and their response to the treatment will be closely monitored. The study aims to understand how well the cancer responds to the treatment and to assess any side effects that may occur.

Throughout the study, participants will receive regular infusions of the medications, and their health will be monitored by healthcare professionals. The study will help determine if this combination of treatments can improve outcomes for patients with metastatic pancreatic cancer. The results of this study could provide valuable information for future treatment options for this challenging disease.

During the study, participants will receive one of the treatments, and their health will be monitored over time. The study will look at how long patients live without the cancer progressing, as well as their overall survival, changes in body weight, pain levels, and quality of life. The study will also explore changes in certain blood markers and other health indicators. The treatments are given through injections, and the study aims to understand the safety and effectiveness of these methods in managing pancreatic cancer.

Participants will be followed up regularly to assess their health and any changes in their condition. The study will continue until 2027, and it aims to provide valuable information on new ways to treat pancreatic cancer, potentially improving the lives of those affected by this challenging disease.

The purpose of the study is to evaluate how effective the sequence of chemotherapy treatments is and to assess how well patients tolerate the radiotherapy. Participants will first receive the chemotherapy treatments, followed by the radiotherapy if their cancer has not progressed. The study will monitor patients over a period to see how the cancer responds to the treatments and to check for any side effects.

Throughout the study, the focus will be on understanding the benefits of the treatment sequence and ensuring the safety and well-being of the participants. The study aims to provide valuable information on the effectiveness of combining these treatments for patients with locally advanced pancreatic cancer.

Participants in the study will receive an injection of the 18F-FAPI-74 solution, which is a chemical substance designed to highlight cancerous areas during a scan. The scan, known as a PET/CT, combines two types of imaging to provide detailed pictures of the inside of the body. This helps doctors identify if the cancer has spread to lymph nodes, which are small glands that are part of the immune system.

The study will follow patients who have either primary or recurrent pancreatic cancer. It aims to see if the 18F-FAPI-74 PET/CT scan can detect cancer spread with at least 70% accuracy. This research could improve how doctors diagnose and treat pancreatic cancer by providing more precise information about the disease’s progression.

The purpose of this research is to determine if giving FOLFIRINOX treatment both before and after surgery (perioperative) leads to better survival outcomes compared to giving it only after surgery (adjuvant). The study will compare these two different approaches to treatment timing in patients who can have their pancreatic cancer surgically removed.

During the study, patients will receive the same combination of medications but at different times in relation to their surgery. The treatment will continue for several weeks, with regular medical check-ups to monitor the patient’s condition. The medications work together to stop cancer cells from growing and dividing, with each drug playing a specific role in fighting the cancer.

The purpose of this study is to determine which treatment is more effective for patients who are not able to undergo full-dose combination chemotherapy. Participants in the study will be randomly assigned to receive either the standard dose of Gemcitabine or the reduced-dose combination of Gemcitabine and Abraxane. The study will monitor the participants over a period of time to see how the treatments affect their cancer and overall health. The main focus will be on how long the patients live without their cancer getting worse, known as progression-free survival. Other aspects such as overall survival, response to treatment, number of hospitalizations, and quality of life will also be assessed.

This study is designed for patients who are considered fragile or not suitable for full-dose chemotherapy. It aims to provide insights into the best treatment options for these patients, helping to improve their quality of life and manage their condition more effectively. The study will continue until December 2026, with the goal of gathering comprehensive data on the effectiveness and safety of these treatment options.

The study will use two different treatment approaches. Some patients will receive nivolumab alone, while others will receive a combination of nivolumab and ipilimumab. Both medications are given through an intravenous infusion, which means they are delivered directly into a vein. The medications being tested are designed to boost the immune system’s ability to detect and destroy cancer cells.

During the study, doctors will monitor how patients respond to the treatment and track any side effects that may occur. The study will look at whether tumors shrink or stop growing in response to the treatment, and how long patients survive without their cancer getting worse. This research may help develop new treatment options for patients with these types of advanced cancers.

The purpose of the study is to optimize a scanning technique known as MR-hyperpolarisation in patients with pancreatic cancer. This technique uses the hyperpolarized pyruvate to enhance the quality of images obtained from the pancreas and other related areas, such as the liver. The study aims to gather baseline data on how this technique works in different parts of the body, including both cancerous and non-cancerous tissues. Additionally, the study will confirm the safety and feasibility of using hyperpolarized pyruvate in these patients.

Participants in the study will receive the hyperpolarized pyruvate injection, and then undergo MR-hyperpolarisation scanning. The study will explore how the signals from this scanning technique relate to the patients’ response to chemotherapy, which will be further tested in future studies. The trial will help researchers understand the potential of this imaging method in improving the diagnosis and treatment of pancreatic cancer.

The purpose of this research is to determine how well this new imaging method works in finding and measuring cancer in the pancreas and bile ducts, and how reliable it is when used repeatedly. The study is divided into three parts: the first part looks at how the imaging substance moves through the body, the second part tests how consistent the results are when the scan is repeated, and the third part examines how accurate the method is in detecting cancer and monitoring treatment response.

During the study, participants will receive intravenous injections of the imaging substance and undergo PET/CT scans. Some participants may have multiple scans to test how well the imaging technique works over time. The maximum amount of radioactive substance used in each scan is 345 megabecquerels (a unit used to measure radioactivity), and the imaging procedure typically takes place within one day.

Participants in the study will receive the treatments through an intravenous infusion, which means the medication is given directly into a vein. The study will take place over a period of time, with regular monitoring to assess how the cancer responds to the treatment. The study aims to understand if the combination of these treatments can improve outcomes for patients with inoperable pancreatic cancer.

Throughout the study, researchers will track various outcomes, such as how long patients live without the cancer getting worse and overall survival rates. The study will also look at how many chemotherapy cycles patients can complete before the treatment is no longer effective. This research is important for finding new ways to treat pancreatic cancer and potentially improve the quality of life for those affected by this disease.

The purpose of this study is to evaluate the safety and effectiveness of PBP1510 when given alone and in combination with gemcitabine. The study is divided into two parts. In the first part, the focus is on understanding how safe and tolerable PBP1510 is for patients. In the second part, the study aims to determine how effective the treatment is when used with gemcitabine. Patients participating in the study will receive the treatment through an intravenous infusion, which means the medication is given directly into a vein.

Throughout the study, patients will be monitored for any side effects and how their bodies respond to the treatment. The study will also look at how the treatment affects the cancer and whether it helps in reducing the size of the tumors. This research is important for developing new treatment options for patients with pancreatic cancer who have not responded to previous chemotherapy treatments.

Participants in the study will be randomly assigned to receive either the oxaliplatin-based or gemcitabine-based chemotherapy. The study will also include other medications such as fluorouracil, calcium folinate, irinotecan, and capecitabine. These medications are commonly used in cancer treatment and will be administered through intravenous use, except for capecitabine, which is taken orally. The study will monitor patients over a period of time to see how well they respond to the treatment and to track their disease-free survival, which means the length of time they remain free from cancer after treatment.

The trial aims to provide valuable information on whether a personalized approach using genetic markers can improve outcomes for patients with pancreatic cancer. By comparing the two methods of treatment allocation, the study hopes to find the best way to increase the time patients remain cancer-free and improve their overall survival. The study will also assess the quality of life and safety of the treatments, including any side effects that may occur.

The treatment involves several chemotherapy medications: fluorouracil, gemcitabine, irinotecan, capecitabine, oxaliplatin, and calcium folinate. Most of these medications are given through an infusion into a vein, while capecitabine is taken as an oral medication. The treatment period may last up to six months.

The study compares two different approaches: one group receives chemotherapy before surgery followed by standard treatment (surgery and additional chemotherapy), while the other group receives the standard treatment only (surgery followed by chemotherapy). The goal is to determine if giving chemotherapy before surgery can help reduce early deaths and help patients live longer overall.

The purpose of this study is to determine the safety and effectiveness of combining BOLD-100 with FOLFOX chemotherapy in treating these types of cancers. The study is conducted in two parts. In the first part, different dose levels of BOLD-100 will be tested to find the safest and most appropriate dose. In the second part, the selected dose will be given to more patients to further study how well the treatment works.

During the study, participants will receive BOLD-100 and FOLFOX through an intravenous line (a small tube inserted into a vein). The medications will be given according to a specific schedule determined by the healthcare team. Throughout the treatment, patients will have regular check-ups to monitor their health and how well the treatment is working.

The study is divided into several parts. In some parts, patients will receive tisotumab vedotin alone, while in others, it will be given alongside pembrolizumab or both pembrolizumab and a platinum agent like cisplatin or carboplatin. These medications are administered through an intravenous infusion, which means they are given directly into the bloodstream through a vein. The study will observe the effects of these treatments over time to understand their impact on the cancer and any side effects that may occur.

The purpose of this study is to assess the antitumor activity of tisotumab vedotin and its combinations in treating these advanced cancers. The study will monitor how the tumors respond to the treatment, how long it takes for a response to occur, and the overall survival of the patients. This information will help determine the effectiveness and safety of the treatment options being tested.

The purpose of the study is to see if Tislelizumab can help improve the time patients remain free from cancer after treatment, known as disease-free survival. Patients will receive either Tislelizumab or a placebo and will be monitored over a period of time to assess their health and any changes in their condition. The study will involve regular check-ups and assessments to track the progress of the patients and the effectiveness of the treatment.

Participants in the study will be those who have completed their initial cancer treatments, such as surgery or chemotherapy, and have been identified as having MRD. The study will include patients with certain types of cancer, such as non-small cell lung cancer, colorectal cancer, pancreatic cancer, and soft-tissue sarcoma. The trial aims to provide valuable information on whether Tislelizumab can offer additional benefits in preventing cancer recurrence in these patients.

The purpose of the study is to determine how well these treatment combinations work in controlling the cancer and improving patient outcomes. Participants in the study will receive one or more of these medications, and some may receive a placebo. The study will monitor the response of the cancer to the treatment, how long the cancer is controlled, and any side effects experienced by the participants. The study will also look at changes in vital signs, such as heart rate and blood pressure, and other health indicators over time.

Throughout the study, participants will have regular check-ups and tests to assess their health and the progress of the treatment. The study is expected to continue until 2025, allowing researchers to gather comprehensive data on the effectiveness and safety of these treatment combinations for metastatic pancreatic ductal adenocarcinoma.

The purpose of the study is to gather initial data on the effects of this treatment in patients who are at high risk for developing fistulas after surgery. The treatment involves using autologous pancreatic islets, which are cells taken from the patient’s own pancreas. These cells are then infused back into the patient through a method called intraportal infusion, which means they are delivered into the portal vein, a major blood vessel leading to the liver.

Participants in the study will undergo surgery to remove part or all of their pancreas, followed by the transplantation of their own islet cells. The study will monitor various outcomes, including the time it takes for patients to be ready for additional treatments after surgery, the occurrence of any complications, and the overall quality of life following the procedure. The study aims to provide valuable insights into the potential benefits and risks of this innovative treatment approach for patients with pancreatic cancer.

Participants in the study will first receive the combination of FOLFIRINOX, pembrolizumab, and SABR. After this initial treatment, patients will undergo surgery to remove the cancer if possible. Following surgery, patients will receive more FOLFIRINOX and pembrolizumab to help prevent the cancer from returning. The study aims to see if this approach can help patients live longer without the cancer progressing.

The study will also look at other important outcomes, such as overall survival, the success rate of surgeries, and the side effects of the treatments. Additionally, it will assess the quality of life of participants and how well they respond to the treatments. This trial is part of ongoing research to find better ways to treat pancreatic cancer and improve outcomes for patients with this challenging disease.

The purpose of the study is to assess the safety and tolerability of AZD9574 in patients with these advanced cancers. Participants will receive the medication in the form of a film-coated tablet taken orally. The study will monitor how the body processes the drug, its effects on the cancer, and any side effects that may occur. Some participants may receive a placebo for comparison. The study will also explore how the drug affects specific biomarkers, which are indicators of how the body is responding to the treatment.

Throughout the study, participants will undergo regular health checks, including blood tests and imaging scans, to track their progress and the impact of the treatment. The study aims to gather information over a period of time to determine the potential benefits and risks of AZD9574 for treating these types of cancers. This research is important for developing new treatment options for patients with advanced solid tumors.